An economic evaluation of adjuvant trastuzumab therapy in HER2-positive early breast cancer.

Abstract

OBJECTIVE One-year adjuvant trastuzumab therapy increases disease-free and overall survival in the adjuvant treatment of early HER2-positive breast cancer. This study aims to assess the long-term cost-effectiveness of adjuvant trastuzumab treatment in Beijing, Shanghai, and Guangzhou. METHODS A Markov health-state transition model was constructed to… (More)
DOI: 10.1111/j.1524-4733.2009.00634.x

Topics

Cite this paper

@article{Chen2009AnEE, title={An economic evaluation of adjuvant trastuzumab therapy in HER2-positive early breast cancer.}, author={Wen Chen and Zefei Jiang and Zhimin Shao and Qiang Sun and Kun-wei Shen}, journal={Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research}, year={2009}, volume={12 Suppl 3}, pages={S82-4} }